A new Cohort 8 study aims to reopen the non-walking patient market with data expected by the end of 2026.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Sarepta Stock Dips After Hours: DMD Drug Blow And CEO Exit Eclipse Q4 Revenue Beat